Christopher Church

Head of Technology Search and Evaluation, BD&L, AZ Biopharmaceuticals R&D

Greater Cambridge Area

About

Experienced scientist (PhD, MBA) with a demonstrated history of working in the biopharmaceutical industry. Skilled in drug discovery, project leadership, business development including search & evaluation, and matrix team management.

Experience

  • AstraZeneca (7 yrs 5 mos)
    • Head of Technology Search and Evaluation, Strategy and BD&L
      Nov 2024 - Present · 1 yr 8 mos

    • Head of Technology Search and Evaluation and Transactions, BD&L
      Apr 2024 - Oct 2024 · 7 mos

    • Senior Director, Search & Evaluation, Business Development, Licensing & Strategy (BDL&S)
      Jul 2023 - May 2024 · 11 mos

      Search and Evaluation for AZ Cardiovascular, Renal and Metabolism (CVRM), Business Development and Licensing (BD&L). Identification and evaluation of external in-licensing opportunities from academia, biotech's and peer-pharma for CVRM. Open to explore all drug modalities from discovery through to late clinical stages.

  • MedImmune (4 yrs 4 mos)
    • Manager, Partnering and Strategy
      Sep 2018 - Feb 2019 · 6 mos

    • Scientist II
      Apr 2018 - Aug 2018 · 5 mos

    • Scientist I
      Nov 2014 - May 2018 · 3 yrs 7 mos

      Adipose Tissue Biology

  • Yale School of Medicine (2 yrs 5 mos)
    • Visiting Research Scientist- Comparative Medicine
      Nov 2014 - Jun 2015 · 8 mos

    • Postdoctoral Associate
      Feb 2013 - Oct 2014 · 1 yr 9 mos

      Adipose Tissue Biology: The Molecular and Cellular Regulation of Adipocyte Precursors in Obesity

  • Postdoctoral Research Fellow at EMBO Postdoctoral Fellow, Yale University
    Jan 2011 - Jan 2013 · 2 yrs 1 mo

    EMBO Postdoctoral Fellow

  • Postgraduate Student at Medical Research Council
    Jun 2006 - Dec 2010 · 4 yrs 7 mos

    Genome wide association studies (GWAS) have proved successful in identifying novel loci for type 2 diabetes, obesity and metabolic disease. My research focused around proving evidence for which genes account for the observed single nucleotide polymorphism (SNP) phenotype. I generated and characterized mouse models to investigate the metabolic effects of the human fat mass and obesity associated FTO gene.